COMPARISON OF KNOWLEDGE LEVELS OF SWIMMING COACHES ABOUT DOPING AND ERGOGENIC AIDS

Most athletes consider their coaches as the most important source of information on nutrition and doping. The aim of this study was to determine the level of knowledge of swimming coaches about doping and ergogenic aids. Method: This study consisted of 148 randomly selected swimming coaches educated in the development Seminar of Swimming Coaches of Rize Ministry of Youth and Sports between April 23-27, 2019. The survey prepared by taking expert opinion. It totally consists of 19 items, 9 of which aim to determine demographic information and 10 of them to determine doping knowledge level. Frequency (f), percentage (%), chi-square test, independent sample t-test and one-way analysis of variance (ANOVA) used for data analysis. Results and discussion: According to the results of the study, when the participants' coaching experience and degree of coaching certificate were compared with the other variables, a statistically significant difference was found (p <0.05) but there was no significant difference between the other variables (p> 0.05). According to the results of the study, it is unclear to what extent the participants who have more coaching experience transfer information to their athletes despite the high level of knowledge about doping and ergogenic aids. In addition, it is thought that the education given in doping and ergogenic aid in universities is insufficient.  Article visualizations

The use of a silicone-coated acrylic vaginal stent in McIndoe vaginoplasty and review of the literature concerning silicone-based vaginal stents: a case report

<p>Abstract</p> <p>Background</p> <p>Mc Indoe vaginoplasty is one of the mostly performed surgical interventions in Mullerian agenesis.</p> <p>Case presentations</p> <p>We present our experience on the use of a new designed vaginal stent that was coated with silicone in two mullerian agenesis cases who had Mc Indoe vaginoplasty. Both full thickness and splitt thickness skin graft were used with the stent. No graft loss or hyperthrophic scarring which may be seen at the apex of neovagina after Mc Indoe vaginoplasty was observed during the follow-up period and adequate neovaginal depth were obtained in both of the patients.</p> <p>Conclusion</p> <p>We think that the incorporation of silicone to a vaginal stent for postoperative wound care improves skin graft take and decreases a possible constriction band formation in neovagina.</p

PALM-COEIN classification system of FIGO vs the classic terminology in patients with abnormal uterine bleeding

Objectives: To evaluate the FIGO’s novel classification system versus the classic terminology in patients with abnormal uterine bleeding. Material and methods: A retrospective study was carried out between August 2015 and September 2019 in the Health Sciences University Gazi Yaşargil Training and Research Hospital. The pathology reports of the patients were classified according to the PALM-COEIN method and were compared with classical terminology. The operated patients with fibroids reported in the pathology results were classified as subgroups of fibroids. Results: Evaluation was made of a total of 515 women with abnormal uterine bleeding. According to the classical terminology, 137 (26.6%) patients were defined with hypermenorrhea, 74 (14.4%) with menorrhagia, 57 (11.1%) with metrorrhagia, and 246 (47.8%) with menometrorrhagia. In the PALM-COEIN classification system, polyps were determined in 84 (16.3%) cases, adenomyosis in 228 [diffuse adenomyosis: 196 (38.1%), local adenomyosis: 32 (6.2%)], leiomyoma in 386 [submu-cous: 161 (31.1%), other types: 225 (43.9%)], and malignancy and hyperplasia in 47 (9.1%). Conclusions: The classical terminology for abnormal uterine bleeding is insufficient in terms of etiological pathologies in non-pregnant women of reproductive age. The widespread use of this novel system for the abnormal uterine bleeding classification will provide a more useful communication between physicians and researchers

Prognostic significance of omental disease and the role of omentectomy in non-endometrioid endometrial cancer

Objectives: Non-endometrioid endometrial cancers (non-EEC) have different management from endometrioid endometrial cancers. The purpose of this study was to investigate the prognostic significance of omental disease and the role of omentectomy in non-endometrioid endometrial cancer and discuss the current literature with the findings. Material and methods: The study included two hundred-three patients with non-EEC who underwent surgical treatment and follow-up between January 1996 and December 2018 in a University Hospital Gynecologic Oncology Center. The patients were divided into three groups according to whether omentectomy was performed and the presence of omental metastasis. The patient’s demographics, clinical characteristics such as stage, grade, histopathologic type, lymphovascular space invasion (LVSI), myometrial invasion, lymph node involvement, and survival outcomes were compared between the groups. Results: The study included 203 patients. Twenty-five patients (12%) had omental metastases. LVSI was reported in 57.3%, 88.0%, and 43.2% of the non-omentectomy, no-omental metastasis, and omental metastatic groups, respectively (p = 0.001). The 5-year disease-free survival (DFS) and overall survival (OS) rates according to the tumor grade, peritoneal cytology, and lymphadenectomy were also compared and were found to be statistically similar. The five-year OS rates were 70.6% for the group without omental metastases and 16.2% for the group with omental metastases, respectively (p = 0.001). In the group of omentectomy, the five-year DFS rates were 62.2% in cases without omental metastasis and 13.0% in cases with omental metastasis (p = 0.001). The five-year OS rates of 86.3% and DFS rates of 80.0% in the group without omentectomy. Conclusions: In non-endometrioid tumors, the survival rate was better in the group that did not undergo omentectomy. Based on these results, we can say that omentectomy may not be necessary for non-endometrioid tumors whose omentum is found to be normal in intraoperative visual examination

Challenges on the morbidly obese endometrial cancer surgery: Laparotomy or laparoscopy, lymphadenectomy or no lymphadenectomy?

Objectives: A considerable proportion of endometrial cancer patients are morbidly obese. Management of these cases is a serious dilemma. The aim of this study was to investigate the relevance of laparoscopic route and omission of lymphadenectomy as morbidity-reducing strategies in this special population. Material and methods: Endometrial cancer patients’ archival records were retrospectively reviewed and cases with body mass index ≥ 40 kg/m2 were selected. A comparative evaluation of their characteristics and survival rates were performed. Firstly, according to the surgical approach; laparoscopy or laparotomy, and then regarding to performing lymphadenectomy or not. Results: There were 146 patients enrolled in this study. Whereas, significantly higher postoperative complications and longer hospital stays were determined in the laparotomy compared to laparoscopy groups. Five years disease-free and overall survival were not significantly different (83.6% vs 70.7%, p = 0.184 and 83.9% vs 86.6%, p = 0.571, respectively). On the other hand, operation length, postoperative hospitalization time, both intraoperative and postoperative complications were significantly lower in the non-lymphadenectomy compared to the lymphadenectomy groups. However, five-years disease-free and overall survival were not significantly different (77.3% vs 81.3%, p = 0.586 and 87.5% vs 78%, p = 0.479, respectively). Conclusions: Laparoscopic approach and omission of lymphadenectomy are worthy policies in the morbidly obese endometrial cancer patients

Clinicopathologic characteristics and prognosis comparison of the uterine high grade endometrial carcinomas

Objectives: Grade 3 endometrioid adenocarcinomas (G3 EAC), type two endometrial carcinomas (Type 2 EC), and alsouterine carcinosarcomas (UCS) are considered as high-grade endometrial adenocarcinomas. The aim of this study was tocompare the clinicopathologic features and survival of patients with UCS, G3 EAC, Type2 EC.Material and methods: We included two hundred and thirty-five patients in this study. Patients were divided into threegroups according to the type of tumor as uterine G3 EAC (group 1, n = 62), Type 2 EC (serous, clear and mixed types; group 2,n = 93), and UCS (group 3, n = 80). We compared the groups according to age, initial symptom, surgical approach, stage,myometrial invasion (MI), lymph node invasion (LNI), lymphovascular space invasion (LVSI), adjuvant therapy, and survival.When comparing the survival outcomes the Kaplan-Meier analysis was performed.Results: The groups were similar according to age, menopausal status, nulliparity, initial symptoms, stage, LVSI, and LNI.Positive cytology was determined significantly more in group 3. There was a significant difference between the groups interms of myometrial invasion degree. Optimal cytoreduction was similar among the groups. The primary adjuvant treatmentwas chemotherapy for UCS and Type2 EAC whereas radiotherapy was the main adjuvant treatment for G3 EAC. Therewere no significant differences among the groups according to overall survival (OS) (p = 0.290).Conclusions: Although the survival difference among the groups can not be revealed, these patients have different clinicaland pathological features and they should be considered as different groups

Klomifen ve HMG/HCG ile indüklenen sikluslarda luteal fazın değerlendirilmesi: kısa lüteal faz, lüteal faz yetmezliği

TEZ1003Tez (Uzmanlık) -- Çukurova Üniversitesi, Adana, 1991.Kaynakça (s. 33-40) var.40 s. ; 30 cm.

Efficiency of ondansetron and tropisetron in cisplatin based cancer chemotherapy

AMAÇ: Over kanseri tanısıyla postoperatif sisplatin-siklofosfamid uygulanan hastalarda kemoterapi sonrasında görülen bulantı ve kusmanın önlenmesi için kullanılan tropisetron ve ondansetron'un etkinliğini karşılaştırmak. HASTALAR VE YÖNTEM: Hastalar rasgele seçmeyle 2 gruba ayrıldı. Hastalara 3 haftada bir olmak üzere 5-8 kür kemoterapi verildi. Tropisetron grubunda toplam 168, ondansetron grubunda toplam 154 kür uygulama yapılmıştı. Ondansetron grubundaki hastalara kemoterapiden 15-30 dakika önce ve 12 saat sonra olmak üzere iki kez 8 mg ondansetron IV infüzyon seklinde verildi. Daha sonra hastalar 2-6. günler 4 mg/gün oral olarak devam ettiler. Tropisetron grubunda ise yine kemoterapiden 15-30 dakika kadar önce 5 mg IV infüzyon seklinde ve daha sonra 2-6. günler 5 mg oral olmak üzere tropisetron verildi. Hastalarda bulantı-kusma sayısı saptandı. Sonuçlar t-pair yöntemiyle karşılaştırıldı. BULGULAR: Tropisetron grubunda ilk 24 saat olguların %37.0 sinde, 2-6. günler arasında %79.1 inde bulantı kontrol altına alınırken ondansetron grubunda aynı rakamlar sırasıyla %39.6 ve %70.7 idi. Kusma kontrolü açısından sonuçlara bakıldığında tropisetron grubunda ilk 24 saat içerisinde %79.1, 2-6. günler arasında %94.6 oranında basarı sağlanırken ondansetron grubunda aynı rakamlar sırasıyla %82.4 ve %92.8 olarak saptandı. Gruplar arasındaki fark istatistiksel olarak önemsizdi (p>0.05). Her iki grupta da belirgin bir yan etki görülmedi. SONUÇ: Her ne kadar tropisetron grubu ilk 24 saatde kusmaları önlemede daha etkili gibi görünsede anlamlı bir farklılık saptanmadı.İlaç seçiminde ajanın kolay bulunabilirliği ve fiatı düşünülerek seçim yapılmasının uygun olduğuna karar verildi.OBJECT:The aim of the study was to compare the efficiency of ondansetron and tropisetron in controlling the nausea and vomiting induced by cisplatin based chemotherapy in patients with ovarian carcinoma MATERIAL AND METHODS: Sixty patients were randomised to receive either ondansetron or tropisetron. Ondansetron (2x8 mgr) and Tropisetron (5 mg/day) were administered by intravenous route in the first day of chemotherapy. During the following 5 days, ondansetron (4 mg/day) and tropisetron (5 mg/day) were administered orally. RESULTS: Each patient was treated with 5-8 courses of chemotherapy. Statistical analysis was performed with t-pair test. At the end of the study, tropisetron and ondansetron had been used for 168 and 154 courses, respectively. The success rates of ondansetron and tropisetron in preventing acute emesis were 82.4% and 79.1%, respectively (p>0.01). Ondansetron was 92.8% and tropisetron was 94.6% effective in preventing delayed emesis (p>0.01). The success rates of ondansetron and tropisetron in preventing acute and delayed nausea were 39.6%, 37.0%, 70.7% and 79.1%, respectively (p>0,01) CONCLUSION: Ondansetron and tropisetron are equally effective for the prophylaxis of nausea and vomiting in cisplatin based cancer chemotherapy